IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
SIMILAR ACR20 RESPONSE SEEN REGARDLESS OF PRIOR ANTI-TNFα EXPOSURE1,2

ACR20 response rates by prior anti-TNFα exposure (DISCOVER 1)

ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.

ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.

TNF=tumor necrosis factor.
*ACR20 response by prior anti-TNFα exposure was a subgroup analysis of the primary endpoint (ACR20 response at Week 24).
Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.
§After Week 24, patients and doctors knew that all patients were on TREMFYA® (open-label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analysis from Weeks 24 to 52 is not shown.

References: 1. Data on file. Janssen Biotech, Inc. 2. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125.